Back to News
Market Impact: 0.35
Blackstone explores sale of ZO Skin Health, sources say
Source: reuters.com
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
Blackstone is exploring a sale of medical-grade skincare company ZO Skin Health, which could be valued at approximately $2 billion, according to people familiar with the matter. A transaction would represent a notable private-equity healthcare/consumer deal, though no buyer, timing, or final terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BX0.20
More News
- Bloomberg Businessweek Daily: Blackstone Chips Bet (Podcast)
- Stocks Fall as Oil Rally Keeps a Lid on Treasuries
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard